Skip to content
Educational information only. Not medical advice. We sell nothing and take no affiliate money.
By /
PeptideNo published researchNot FDA approved

Adamax

Adamax

Last reviewed October 27, 2026 · 10 sources · Written for general readers · Compare with another compound →

The bottom line

We could not find a single published study of adamax, in the lab, in animals or in people. Its structure is not confirmed by any scientific or government source we could find. Every claim made about it, from focus to mood, is untested, and the new federal compounding policy that covers semax does not cover adamax.

Where the evidence stands

What it is

Adamax is a name used online for a product described as a modified version of semax. We could find no published scientific study of it. A PubMed search for adamax returned 39 papers, and every one used the word for a computer learning method, not a peptide.[1] A narrower search pairing adamax with peptide, semax, adamantane or ACTH found only one paper, also about that computer method.[2] A wider search of the Europe PMC research database found the same thing.[3]

Because nothing has been published, its exact chemical structure has not been confirmed by any scientific or government source we could find.

Semax, the compound it is said to be based on, is a lab made chain of seven amino acids that copies part of ACTH, a pituitary hormone, with an added end piece that makes it harder to break down.[4] Semax itself is poorly studied outside Russia, and FDA staff judged its evidence too weak to support pharmacy compounding.[4] FDA's review of semax does not mention adamax or any modified semax.[4]

Name
Adamax (Adamax)
Type
Peptide

What it does in the body

Nobody has published what adamax does in the body, and no scientific or government source confirms its structure.[1][3] The only biology to point to belongs to semax, the peptide it is said to be based on, and every effect below was seen with semax in animals, not with adamax.[4]

This is the biology, area by area. A change measured in the body, like a higher blood level, does not always mean a person feels a benefit. The claims check below covers that.

Brain and memory

Seen in animals

In rats, FDA's review describes a nasal dose of semax raising BDNF and NGF, growth factors that help nerve cells survive and connect, in brain areas including the hippocampus within about an hour.[4] No one has measured this after adamax.

Brain after a stroke

Seen in animals

In rats with a blocked brain artery, semax was linked to about 20% smaller areas of brain damage after 8 days.[4] Adamax has never been tested in any stroke model.

Dopamine and reward

Seen in animals

In mice, semax boosted the dopamine release and extra movement caused by amphetamine. FDA called this concerning because drugs of abuse act on the same dopamine system, and no abuse studies exist.[4] Whether adamax shares this is unknown.

Blood and clotting

Seen in animals

Rat studies found semax increased the breakdown of blood clots and reduced platelet clumping, though FDA notes these effects were not tested at different strengths.[4] Nothing is known about adamax and clotting.

How it works

No one has published how adamax works.[1][3]

  • Any claim that it works like semax is a guess. Even for semax, FDA says the way it works is poorly understood.[4]
  • Ideas proposed for semax include blocking enzymes that break down the body's own calming chemicals, raising brain growth factors and changing gene activity, but FDA says none is confirmed.[4]

There is no evidence to judge for adamax itself, so certainty is essentially zero.

What the research shows

We keep animal and human evidence apart. A result in animals is a reason to study something in people, not proof that it works in people.

Animal and lab studies

No animal studies found

  • We found no published animal or lab studies of adamax.[1][2][3]
  • Animal studies of semax exist, mostly from Russia, but they cannot stand in for adamax, a different molecule whose structure is not even published.[4]

Limit: Without animal data, nothing is known about its effects or its toxicity.

Human studies

No human studies found

  • We found no published human studies of adamax. No one has reported what people experienced, how long effects lasted, or what side effects occurred.[1][3]
  • For comparison, FDA found only small, uncontrolled human reports for semax itself and concluded there was not enough evidence that it works for stroke, migraine or nerve pain.[4]

Limit: Effects people describe online are personal stories, not evidence.

Claims check

The most common claims about this compound, and what studies actually found. Verdicts rate the evidence, not whether you should use it.

Sharpens focus and memory

Not tested

No study of adamax exists in people, animals or cells.[1][3] Even for semax, FDA found the evidence too weak to support compounding.[4]

Lifts mood and eases anxiety

Not tested

No published study has tested adamax for mood or anxiety in any setting.[1][3]

Protects the brain and raises BDNF

Not tested

BDNF is a growth factor for nerve cells. No one has published a measurement of BDNF, or any brain effect, after adamax.[1][3] Semax raised BDNF in rats, but that cannot be assumed for a different molecule.[4]

Works stronger and longer than semax

Not tested

No study has compared adamax with semax, or measured how long adamax lasts in the body.[1][3]

Boosts motivation and energy

Not tested

No published study has tested this.[1][3]

Is as safe as semax

Not tested

No safety study of adamax exists.[1] And semax itself has no published acute, repeated dose or reproductive toxicity studies, according to FDA, which also could not rule out immune reactions to impurities.[4]

Known risks and side effects

  • Completely untested. No published safety studies exist, so short term and long term side effects are unknown.[1]
  • Unknown contents. There is no official standard for what adamax is, so buyers cannot know what a vial holds. Even for the better studied semax, FDA found test certificates that allowed unnamed impurities and no data on bacterial toxins, and it could not rule out immune reactions.[4]
  • Borrowed concerns from semax. If adamax acts anything like semax, FDA's worries would apply too: semax boosted amphetamine's dopamine effect in mice, and it has never had standard toxicity testing.[4]
  • Outside FDA oversight. Adamax does not appear on FDA's lists of nominated compounding ingredients or its compounding safety risk lists.[5][6] The October 2026 federal compounding policy covers six peptides, including semax as a nasal product, but not adamax.[7]
  • Sport drug testing. WADA bans substances with no government approval for human use, and its 2027 list names peptides among its examples. That rule appears to cover adamax.[8][9]

Regulatory status

Today: Adamax is not FDA approved, and it does not appear on any FDA compounding nomination or safety risk list.[5][6] HHS's interim compounding policy from October 2026 covers semax in nasal form but not adamax, and WADA's rule on non approved substances appears to cover it.[7][10][9]

  1. FDA's advisory committee reviewed semax. FDA staff said the evidence weighed against allowing it in compounding; adamax was not part of the review.[4]
  2. HHS filed an interim policy to stop enforcement against pharmacy compounding of six peptides, including semax as a nasal product. Adamax is not one of them.[7][10]

Sources

  1. PubMed search for adamax. National Library of Medicine. Searched October 2026; 39 results, none about a peptide. PubMed search
  2. PubMed search for adamax AND (peptide OR semax OR adamantane OR ACTH). National Library of Medicine. Searched October 29, 2026; 1 result, about a computer learning method, not a peptide. PubMed search
  3. Europe PMC search for adamax AND (peptide OR semax). Searched October 2026; 18 results, none about a peptide. Europe PMC search
  4. U.S. Food and Drug Administration. FDA evaluation of semax and semax acetate for the 503A bulks list. Pharmacy Compounding Advisory Committee briefing document, meeting of July 24, 2026. FDA briefing document
  5. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026. FDA
  6. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026. FDA 503A categories list
  7. U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendices A and B. October 2026. HHS policy
  8. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force January 1, 2026. WADA 2026 List
  9. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027, section S0 Non-approved substances. In force January 1, 2027. WADA 2027 List
  10. Steinzor P. 5 Things to Know About HHS's Interim Peptide Compounding Policy. AJMC. October 29, 2026. AJMC news
Medical disclaimer

This page is educational information only. It is not medical advice and does not replace care from a licensed medical provider. Do not use this page to decide whether to take any substance. Talk to a licensed medical provider first.

Found an error or a newer study? We correct pages fast.

Report a correction →
Scroll to Top